"Great Lakes Research Group is a clinical research company based in Bay City, MI. We are committed to actively participating in the advancement of medical care and our community’s health with the vision to help offer patients better care and hope for improved healthcare in the future. Since Great Lakes Research Group opened its doors in 2004, the center has become home to a variety of studies that work to conduct groundbreaking research in osteoarthritis, obesity, diabetes mellitus, chronic low back pain, multiple sclerosis, hypertension, asthma, psoriasis, postherpetic neuralgia, acne, actinic keratosis, endometriosis, and bacterial vaginosis, in addition to other health maintenance studies. Contact us for more information!"

During the past decade, Great Lakes Research Group, Inc. conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 35 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 26 clinical trials were completed. i.e. 92.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Great Lakes Research Group, Inc." #1 sponsor was "Eli Lilly and Company" with 23 trials, followed by "Pfizer" with 8 trials sponsored, "LEO Pharma" with 5 trials sponsored, "BioDelivery Sciences International" with 3 trials sponsored and "Dermira, Inc." with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Great Lakes Research Group, Inc." #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Incyte Corporation" with 3 trials as a collaborator, "AbCellera Biologics Inc." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Shanghai Junshi Bioscience Co., Ltd." with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Great Lakes Research Group, Inc." are "Osteoarthritis" (9 trials), "Atopic Dermatitis" (7 trials), "Low Back Pain" (5 trials), "Diabetic Peripheral Neuropathic Pain" (4 trials) and "Osteoarthritis, Knee" (4 trials). Many other conditions were trialed in "Great Lakes Research Group, Inc." in a lesser frequency.

Most popular intervention types in "Great Lakes Research Group, Inc." are "Drug" (54 trials), "Biological" (8 trials), "Other" (6 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "Baricitinib" (3 trials), "LY3016859" (3 trials), "LY3556050" (3 trials) and "Lebrikizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Great Lakes Research Group, Inc." are 61 trials for "All" genders.

Currently, there are NaN active trials in "Great Lakes Research Group, Inc.". undefined are not yet recruiting, 8 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Great Lakes Research Group, Inc., 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Great Lakes Research Group, Inc., 2 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".